33 C
Vientiane
Monday, May 19, 2025
spot_img
Home Blog Page 466

Creative Schools Continuum Launches Anniversary Celebrations with Charity Walk


HONG KONG SAR – Media OutReach Newswire – 7 March 2025 – On 16 February 2025, more than 800 people gathered at the Creative Secondary School campus in Tseung Kwan O, Hong Kong, China to celebrate the schools’ anniversaries. Participants included school board members, students, parents, alumni, and staff. The event aimed to raise funds for the Community Chest of Hong Kong, which helps over 2.5 million people each year. The school community raised a total of HKD 213,085.

Creative Schools Continuum Launches Anniversary Celebrations with Charity Walk
Creative Schools Continuum Launches Anniversary Celebrations with Charity Walk

The day began early with student-led game booths and photo opportunities, creating a fun and exciting atmosphere on campus. Young leaders from the three schools welcomed guests and families, setting a lively mood before the opening ceremony and charity walks.

Two scenic walk routes were available: a shorter 2.5-kilometer path for families with younger children and a more challenging 5-kilometer route for those looking for a serious workout. Both routes took walkers through the beautiful sights of Tseung Kwan O, including the pedestrian paths from the school campus to the Tseung Kwan O waterfront park and the Cross Bay Bridge, offering stunning views along the way.

In his opening speech, the chairman of the celebration committee Mr. Victor Fong said, “Since Creative Primary School and Creative Primary School’s Kindergarten were founded in 1985, and Creative Secondary School in 2006, we have created high-quality, coherent educational pathways for students from kindergarten to secondary school.”

“The Creative Schools Continuum is fully committed to providing an exceptionally caring and positive learning environment for students, focusing on both academic success and positive character development.”

The idea of combining celebrations with a charity event comes from the core values of the three member schools. They focus not only on fostering students’ academic achievements and lifelong passion for learning but also enhancing their confidence, resilience, strengths of character and personal qualities. This prepares students to take on new opportunities and contribute to a fast-changing and increasingly challenging world.

Factual Highlights of the Creative Schools Continuum
Three Schools * One Philosophy * One Continuum

  • The motto of Creative Schools Continuum is “Nurture Future Minds * Build Boundless Capacity”, highlighting the continuum’s foresights and insights of quality education and our commitments to our students and parents.
  • Creative Primary School and Creative Secondary School are award-winning “Inviting Schools”. The award recognizes the schools’ commitments to providing an exceptionally caring, trusting, respectful and positive learning environments for its students and staff.
  • As International Baccalaureate (IB) World Schools, Creative Primary and Creative Secondary School offer the IB Primary Years Programme (IB PYP), IB Middle Years Programme (IB MYP) respectively.
  • Creative Secondary School also offers the Hong Kong Diploma of Secondary School Examination (HKDSE) course in parallel with the IB Diploma Programme (IBDP) as pathways to university entrances.

Hashtag: #CSS #CPS #CPSKG #CreativeSchoolsContinuum

The issuer is solely responsible for the content of this announcement.

China Telecom and Partners Innovate Together! 5G UAV Medical Delivery Network Wins Global Mobile Award

HONG KONG, March 10, 2025 /PRNewswire/ — On March 5, during the 2025 Mobile World Congress (MWC25), the 5G UAV medical delivery network solution jointly developed by China Telecom, Hangzhou Antwork Network Technology and Zhejiang University was awarded the Global Mobile Award (GLOMO Award) for “Best Mobile Innovation for Connected Health and Wellbeing.” This groundbreaking achievement signifies that the integration of “5G + low-altitude + healthcare” is poised to enter the stage of large-scale application, opening up new pathways for the equitable distribution of medical resources worldwide.


China Telecom, driven by deep insights into the pain points of the healthcare industry and a forward-looking strategic layout, has taken the lead in constructing a 5G-A technology matrix. To address issues such as low efficiency in medical supply delivery and regional resource imbalances, the company has innovatively introduced 5G-A super terrestrial and aerial integration technology alongside a high-precision medical sensing network. This creates a low-altitude medical corridor that is extensive, responsive, and secure. The technology employs a combination of high and low frequencies, using dynamic resource scheduling through smart beamforming in urban areas. In suburban regions, it utilizes new wide-angle power-sharing smart antennas for broad coverage, overcoming geographical limitations. Equipped with perception AS, perception SF, and base station sensing devices, the system enables UAV trajectory tracking, electronic fence protection, and real-time monitoring of multiple targets to ensure flight safety. It supports low-altitude network high-definition video transmission and, combined with UAVs capable of withstanding winds over level 5, significantly enhances transportation efficiency, providing 24-hour immediate response for emergency medical scenarios.

Currently, this solution is being piloted in Zhejiang Province. The use of UAV delivery routes for blood transport has significantly reduced transportation time compared to ground logistics, effectively meeting both “emergency blood use” and “planned blood replenishment” needs, thereby greatly enhancing emergency response speed. By leveraging UAVs as a “highway” for rural areas, an aerial bridge has been established between central hospitals and grassroots health clinics, facilitating the implementation of a tiered healthcare system and allowing for more balanced resource allocation. According to actual flight data, a single UAV flight can meet the emergency blood needs of 1-2 patients, benefiting remote areas with weaker healthcare resources and increasingly demonstrating its social impact.

The success of the 5G-A smart healthcare solution exemplifies the deep integration of “terrestrial and aerial fusion” technology with medical scenarios. UAV medical delivery represents not only a technological breakthrough but also a new paradigm in life-saving operations. In the future, China Telecom will continue to collaborate with partners across the industry chain to further unlock the limitless potential of 5G-A. This initiative aims to catalyze a transformative increase in the overall productivity of vertical industries, injecting new qualitative productivity into the high-quality development of the digital economy.

The Global Mobile Awards (GLOMO), founded by the authoritative organization GSMA in 1996, features a judging panel of over 260 analysts, media representatives, and industry experts as of 2025. It is the most prestigious award in the telecommunications industry, often referred to as the “Oscars of Mobile Communication.” The GLOMO Awards aims to recognize individuals and companies that drive innovation and demonstrate exceptional achievements in the rapidly growing mobile sector.

JustMarkets Sets New Mobile Trading Standards After 10 months of Launch


HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 10 March 2025 – Since June 2024, JustMarkets, a globally recognized broker, has completely transformed its mobile app for traders to access markets with more ease and efficiency. Latest updates have positioned the app as a must-use platform for intuitive experience and trading on-the-go.

JustMarkets Sets New Mobile Trading Standards After 10 months of Launch
JustMarkets Sets New Mobile Trading Standards After 10 months of Launch

“Our priority is to give traders the best tools to succeed. With constant updates and new features on the horizon, our app will keep revamping to meet all the needs of modern traders,” – commented a JustMarkets representative.

Major Achievements and Milestones

Following the app update in 2024, JustMarkets faced notable growth and increased user engagement:

  • More than 200,000 new downloads across iOS and Android — a 55% increase compared to the previous period (August 1, 2024 – February 10, 2025).
  • 8 million sessions recorded — highlighting strong user engagement and demand for JustMarkets mobile trading solutions.
  • Expanded reach among iOS and Android users, with top download regions in Malaysia, South Africa, Jordan, Singapore, Nigeria, Iraq, Egypt and the UAE.


New Features Reshaping the Trading Experience

With a strong focus on user needs, the JustMarkets team refined both iOS and Android, guaranteeing a multifunctional, inclusive, and straightforward experience for every trader.

For Android Users:

  • New deposit bonus procedure to make bonus activation easier.
  • Symbol mini chart on trade screen that provides instant market insights.
  • Top movers & popular tab, highlighting trending assets.
  • New PIN code funnel that enhances account security and accessibility.

For iOS Users:

  • Top movers & popular tab — helping traders track key market trends.
  • Trading operations displayed on chart for a detailed representation of trades.
  • Changes for the new deposit bonus procedure to simplify its claim process.
  • New PIN code funnel that ensures effortless authentication.

User Feedback and Positive Reviews

The JustMarkets app transformations have been met with positive feedback from traders, and it continues to pour in. Here are a few recent comments from the Google Play and App Store review sections:

  • “It’s an amazing app!”
  • “This is the best broker I have ever experienced!”
  • “Been using JustMarkets since the beginning of 2024, and I’ve had no issues — deposits and withdrawals work smoothly, and the spreads are decent!”
  • “Very useful, transparent, and simple.”

What’s Next for JustMarkets Mobile Trading

The JustMarkets mobile trading app is available on Google Play and App Store. Over the past months, it underwent big improvements, making the app more user-friendly, technological, and feature-rich. It all started with the introduction of In-App Trading that allowed users to trade in real time without needing external platforms. Now, traders can seize opportunities right away, keep up with market movements from any place, and enjoy other astonishing benefits the team worked on for the last 8 months.

Looking forward, JustMarkets remains committed to further enhancements. Plans for 2025 include additional trading features, expanded payment options, and even better security measures.
Hashtag: #JustMarkets #MobileApp #JM





The issuer is solely responsible for the content of this announcement.

About JustMarkets

JustMarkets is a globally recognized multi-asset broker providing reliable and transparent trading services since 2012. The company has earned over 60 industry awards, highlighting its excellence in the financial sector. JustMarkets offers a diverse array of trading instruments, including forex, stocks, commodities, indices, metals, energies, and cryptocurrencies, serving clients in over 160 countries.

AIM Vaccine’s Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines

HONG KONG, March 10, 2025 /PRNewswire/ — AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company’s research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medical Products Administration. This product is an upgraded version of the diploid rabies vaccine, featuring significantly high efficacy, marking a major iterative upgrade in the global rabies vaccine technology field. Animal trials have shown that the vaccine generates antibodies that provide a high level of protection, with efficacy significantly surpassing that of already marketed diploid rabies vaccines under the same dosage conditions.

This vaccine has successfully overcome the technical bottlenecks of traditional processes, which are characterized by low virus titer and low yield. Optimizations and innovations have been made in the purification process, resulting in significant improvements in product quality and safety. It can be administered using a five-injection method, a simplified four-injection method, or a 2-1-1 four-injection method, offering more flexibility and convenience.

Since February, AIM Vaccine has made several breakthrough advancements that highlight its innovative capabilities and global strategy. Its mRNA RSV (Respiratory Syncytial Virus) vaccine has received clinical approval in the U.S., and the company announced a comprehensive deployment of the DeepSeek large model, realizing a strategic upgrade to an “AI + Smart Vaccine Enterprise.”

In the context of major global investment banks raising target prices for Chinese assets, biotech stocks with high technological innovation content are expected to encounter significant opportunities. China Galaxy International Securities[1] believes that the pharmaceutical sector will undergo a recovery, and structural opportunities still exist. From the perspective of short-term and medium-to-long-term growth certainty, it is optimistic about the innovative pharmaceutical supply chain, international expansion, and leading companies in niche sectors.

Fosun International Securities[2] previously pointed out that AIM’s innovative products are driving a revaluation of its value. Considering AIM Vaccine’s strong R&D capabilities, technological leadership, and international market expansion potential, it has assigned a “Buy” rating with a target price of HKD 11.

Note 1: http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=GLH1848484L&catg=1&source=GLH

Note 2: http://www.aastocks.com/tc/stocks/news/glh-news/GLH1832345L/1

U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®

  • OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA
  • Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1]
  • The availability of the first omalizumab biosimilar will help increase access and potentially lower the healthcare cost for people with asthma and allergic diseases

JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ — Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU).[2] 

“We are proud to achieve the approval of the first biosimilar to omalizumab in the U.S., which will help broaden access to this important medicine for patients with allergic and respiratory conditions, as well as for physicians, payers and providers,” said Hetal Patel, Vice President of Medical Affairs at Celltrion USA. “The interchangeability designation of OMLYCLO reinforces confidence among physicians and patients that there is no decrease in effectiveness or increase in safety risk associated with switching between OMLYCLO and the reference product.”

The FDA approval and designation of interchangeability are based on comprehensive clinical evidence, including results from a global Phase III clinical trial involving 619 adult patients with CSU up to Week 40. Patients were randomized to receive 300 mg or 150 mg of OMLYCLO or reference product every 4 weeks. From Week 12, patients who received OMLYCLO were continued on OMLYCLO, and patients who received 300mg of the reference product were re-randomized in a 1:1 ratio to switch to OMLYCLO or to continue reference product. From Week 24, patients were followed up until Week 40 without dosing. The result demonstrated the comparable efficacy and safety of OMLYCLO to reference product during both treatment and off-dose periods.[1]

An interchangeable biosimilar is a biosimilar that meets additional requirements outlined by the law that allows for the FDA to approve biosimilar and interchangeable biosimilar medications.[3]

“The approval of OMLYCLO could have a meaningful impact for the medical community and patients, offering a high quality and affordable treatment option, while reducing the burden of healthcare costs,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “With our integrated development, manufacturing, and commercialization platform, Celltrion remains committed to alleviating treatment costs and delivering life-changing medicines to support patients with allergic conditions in the U.S.”

About OMLYCLO® (omalizumab-igec)  

OMLYCLO® (omalizumab-igec) is the first U.S. Food and Drug Administration (FDA)-approved anti-IgE antibody biosimilar referencing XOLAIR® (omalizumab). OMLYCLO 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe is approved as interchangeable with reference product for all indications based on comprehensive data and clinical evidence confirming the therapeutic equivalence to XOLAIR.[1],[2] OMLYCLO was also approved by the European Commission (EC) in May 2024.

INDICATION

OMLYCLO® (omalizumab-igec) injection, is an anti-IgE antibody indicated for: 

  • Moderate to severe persistent asthma in adults and pediatric patients ≥6 years of age with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids
  • Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients ≥18 years of age with inadequate response to nasal corticosteroids, as add-on maintenance treatment
  • IgE-mediated food allergy in adult and pediatric patients aged ≥1 year age for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance
  • Chronic spontaneous urticaria (CSU) in adults and adolescents ≥12 years of age who remain symptomatic despite H1 antihistamine treatment

Limitations of Use: Not indicated for: acute bronchospasm or status asthmaticus; emergency treatment of allergic reactions, including anaphylaxis; other forms of urticaria.

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS

Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab products. Anaphylaxis has occurred as early as after the first dose of omalizumab products, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate OMLYCLO therapy in a healthcare setting and closely observe patients for an appropriate period of time after OMLYCLO administration.

Health care providers administering OMLYCLO should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of OMLYCLO should be based on criteria to mitigate risk from anaphylaxis.

Contraindications: Severe hypersensitivity reaction to OMLYCLO or any ingredient of OMLYCLO.

Anaphylaxis. Omalizumab products, including OMLYCLO, have been associated with anaphylaxis, reported in both clinical trials and postmarketing data. Patients with a history of anaphylaxis to foods, medications, or other causes face an increased risk. Initiate OMLYCLO only in a healthcare setting with anaphylaxis management capabilities. Patients should be monitored for an appropriate period post-administration, informed of symptoms, and instructed to seek immediate medical care if they occur.

Malignancy. Malignancies have been observed in clinical studies, with various cancer types reported. The long-term risk, especially in high-risk groups, is unknown.

Acute Asthma Symptoms and Deteriorating Disease. Omalizumab products have not been shown to alleviate asthma exacerbations acutely. Do not use OMLYCLO to treat acute bronchospasm or status asthmaticus.

Corticosteroid Reduction. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of OMLYCLO therapy for asthma or CRSwNP.

Eosinophilic Conditions. Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy, especially upon reduction of oral corticosteroids.

Fever, Arthralgia, and Rash. Stop OMLYCLO if a patient develops this constellation of signs and symptoms, including arthritis/arthralgia, rash, fever, and lymphadenopathy.

Parasitic (Helminth) Infection. Monitor patients at high risk of geohelminth infection while on OMLYCLO therapy.

Laboratory Tests. Omalizumab increases serum total IgE due to drug:IgE complexes. Do not use serum total IgE levels within one year of discontinuation to reassess dosing regimen, as they may not reflect steady-state free IgE.

Potential Medication Error Related to Emergency Treatment of Anaphylaxis. OMLYCLO should not be used for the emergency treatment of allergic reactions, including anaphylaxis. Instruct patients that OMLYCLO is for maintenance use to reduce allergic reactions, including anaphylaxis, while avoiding food allergens.

Most Common Adverse Reactions

  • Asthma: In patients ≥12 years, reported in ≥1%: arthralgia, general pain, leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. In pediatric patients (6 to <12 years), reported in ≥3%: nasopharyngitis, headache, pyrexia, upper abdominal pain, streptococcal pharyngitis, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.
  • CRSwNP: In ≥3% of adults: headache, injection site reactions, arthralgia, upper abdominal pain, and dizziness.
  • IgE-Mediated Food Allergy: In ≥3% of patients: injection site reactions and pyrexia.
  • CSU: In ≥2% of patients: nausea, nasopharyngitis, sinusitis, upper respiratory tract infections (viral and non-viral), arthralgia, headache, and cough.

For more information, see Full Prescribing Information.

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us. and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has nine biosimilar products approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com, and stay updated with our latest news and events on our social media: LinkedIn.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

OMLYCLO® is a registered trademark of CELLTRION, Inc.
XOLAIR® is a registered trademark of Novartis AG.

References

[1] Sarbjit Singh Saini et al., CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study. Available at: https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.16446?msockid=30d535870b30638b14c920090a18627c  [Last accessed March 2025]

[2] OMLYCLO U.S. prescribing information (2025)

[3] U.S. Food and Drug Administration (FDA). Available at: https://www.fda.gov/drugs/things-know-about/9-things-know-about-biosimilars-and-interchangeable-biosimilars [Last accessed March 2025]

US-OML-25-00001

For further information please contact: 
Andria Arena
aarena@jpa.com
+1 516-578-0057

Appian Unveils Latest Platform Release for Faster, More Powerful Data Fabric and AI Experience

SYDNEY, March 10, 2025 /PRNewswire/ — Appian (NASDAQ: APPN) today announced the latest version of the Appian Platform, which delivers improved scalability, speed, and performance for enterprise applications. Appian 25.1 introduces more document processing capacity with AI skills, centralised dashboards for monitoring process KPIs, and the ability to sync 10 million rows per record type in your data fabric.

Appian 25.1 allows you to process 75x more documents per hour. Extract and classify data from more pages, faster, with Appian AI skills.
Appian 25.1 allows you to process 75x more documents per hour. Extract and classify data from more pages, faster, with Appian AI skills.

With the platform’s improved AI architecture, organisations can now classify or extract data from hundreds of millions of pages per year with AI skills. Even applications handling high volumes of documents will experience fewer delays and bottlenecks with improved processing capabilities of up to 75 times more documents per hour.

“The results we experienced in the beta program exceeded our expectations,” said Rob Turverey, Director of Learning and Delivery at Groundswell. “We were hoping it would be 50% faster and were excited to see a 5x improvement! We believe these performance improvements will have a big impact on our customers.”

Data fabric architecture enhancements in 25.1 support greater scalability and performance throughout applications and in Process HQ. Updates include:

  • Performance improvements in Appian sites and applications: Participants of the data fabric enhancements beta program experienced 5–10 times faster performance for complex queries against record types with millions of rows – with some queries up to 40 times faster.
  • Improved data fabric scalability: Users can sync up to 10 million rows in each record type and store unstructured data in record fields to meet organisations’ growing data needs.
  • Comprehensive field-level security: New field-level security configurations offer greater control and compliance, supplementing existing record-level security settings across applications and Process HQ.

“We participated in the beta program for these new data fabric enhancements to evaluate the performance of our high-volume datasets with data fabric insights,” stated Michael D’Itri, Manager of Wireless DevOps Data & Tools at TELUS. “We were really happy with the performance and as a result, we are committed to investing further in the Appian data fabric capabilities this year.”

Appian 25.1 also enables users to add key performance indicators (KPIs) for processes to dashboards, allowing organisations to centralise information from process insights and data fabric insights. Users can drag and drop process KPIs onto the dashboard to view all relevant data in one place and link each KPI to a process for quick navigation.

The Appian Platform already makes it easy to build intuitive, information-dense interfaces. This release delivers component improvements that enhance UI experience, including editable grids, form layout formatting, and record components.

“Making AI valuable requires injecting it into business processes,” said Michael Beckley, CTO and Founder of Appian. “Appian 25.1 makes AI valuable by combining large language models with Appian’s class-leading autoscale process engine and Appian’s unique data fabric.”

Beckley continued, “Data fabrics are increasingly the preferred data plane in companies’ AI stacks, but most are optimised for read-only access and don’t scale well for writes beyond 2,000 rows per record. For Appian 25.1, Appian’s data fabric natively reads and writes 10 million rows per record, enabling AI to be reliably injected into mission-critical processes in all industries.”

For more information about the latest Appian Platform release, please visit appian.com/whats-new.

About Appian

Appian is The Process Company. We deliver a software platform that helps organisations run better processes that reduce costs, improve customer experiences, and gain a strategic edge. Committed to client success, we serve many of the world’s largest companies across industries. For more information, visit appian.com. [Nasdaq: APPN]

Follow Appian: LinkedIn, X (Twitter)

 

HKA WELCOMES FORENSIC ACCOUNTING EXPERT JACQUELINE WOODS TO HKA IN AUSTRALIA

SYDNEY, March 10, 2025 /PRNewswire/ — HKA, a leading global consultancy in risk mitigation and dispute resolution, is excited to announce that Jacqueline Woods has joined its rapidly expanding Forensic Accounting and Commercial Damages (FACD) team in Sydney, Australia. Jacqueline brings over 25 years of expertise in forensic accounting, particularly in valuations and loss quantification, bolstering HKA’s capability to address client needs in complex disputes.

Jaqueline Woods
Jaqueline Woods

Jacqueline’s career spans various sectors, where she has successfully resolved financial disputes as an independent expert in commercial litigation, family law and personal injury contexts. Jacqueline is also an accredited Expert Determiner, allowing her to resolve disputes as a single expert acting for both parties without the need for formal litigation.

Stuart Ells, Forensic Accounting and Commercial Damages Lead and Chief Growth and Operations Officer, International, stated, “I’m pleased to welcome Jacqueline as another senior member of our growing team of FACD Experts in Australia. Jacqueline’s extensive experience in forensic accounting, particularly her focus on valuations in shareholder disputes and family law, complements our existing service offerings and makes her an invaluable addition to the team in Australia and internationally. We are thrilled to welcome her aboard.”

Jacqueline’s educational credentials include a Master of Accounting and Economics from the University of Dundee, Scotland, and she is a Chartered Accountant and Expert Determiner. She has been involved in many significant engagements, such as expert determinations for shareholder agreements and post-acquisition disputes and financial investigations for transactions fraught with fraud risks. Her pragmatic approach and energetic demeanour will be instrumental in enhancing HKA’s service offerings.

“I am excited to join HKA during this period of growth and contribute to a team known for its excellence in forensic accounting,” said Jacqueline Woods. “I look forward to collaborating with my esteemed colleagues, leveraging our collective knowledge to provide tailored solutions that meet our clients’ diverse needs.”

Jacqueline’s inclusion in the FACD team follows the recent appointment of partners Andrew Ross, Anh Nguyen, John Temple-Cole, Sally Davitt, and Director Elizabeth Buchanan, who collectively enhance HKA’s footprint in the Asia Pacific market and internationally. With a combined wealth of knowledge and a robust approach to handling domestic and cross-border disputes, HKA continues to establish itself as a leader in the forensic accounting domain.

Jacqueline’s expertise further solidifies HKA’s position in providing comprehensive forensic accounting services across various jurisdictions.

For more information, visit www.hka.com 

Contact:
Peita Calvert
peitacalvert@hka.com

Aeroband Hits the Right Note at SXSW: The Best Smart Musical Instrument Brand Inspiring the Future of Music

Unleash the Rhythm of Inspiration at SXSW with Aeroband

AUSTIN, Texas, March 10, 2025 /PRNewswire/ — Aeroband, a leader in smart music technology, announces its participation at the 2025 South by Southwest (SXSW) Festival. At the event, Aeroband showcases its innovative products, including the Aeroband Guitar and PocketDrum, offering attendees an immersive music experience that celebrates creativity, innovation, and music culture.

Aeroband, known for transforming how people create and experience music, proudly presents its products at SXSW, a festival renowned for showcasing cutting-edge technologies and creative innovations. Aeroband Guitar and PocketDrum empower creators to make music anywhere, anytime. These products are perfect for both beginners and seasoned musicians, offering intuitive designs and powerful functionality that enhance the music-making experience.

Aeroband at SXSW Conference & Festivals 2025
Aeroband at SXSW Conference & Festivals 2025

Event Highlights

Interactive Booth – Austin Convention Center, Booth 209: Aeroband invites SXSW attendees to Booth 209 for an immersive, hands-on experience with the Aeroband Guitar and PocketDrum. Visitors will have the opportunity to explore the full capabilities of these innovative instruments, designed to make music creation more intuitive and accessible.

SXSW Instagram Engagement: As part of our commitment to fostering musical creativity, Aeroband is hosting a social media engagement activity at the booth. Attendees are encouraged to capture their experience with Aeroband Guitar or PocketDrum, share it on Instagram, and tag @aerobandofficial. Participants who complete this step will be entered into a giveaway, with a chance to win a PocketDrum. Winners will be randomly selected and notified after the event.

As a pioneer in smart musical instruments, Aeroband continues to revolutionize music technology with Aeroband Guitar and PocketDrum-designed for musicians of all levels. By integrating intuitive design, portability, and advanced digital capabilities, Aeroband empowers users to play, practice, and create music effortlessly, anytime, anywhere.

“At Aeroband, we believe technology should break barriers. Our goal is to make music more accessible, intuitive, and enjoyable for everyone—from beginners taking their first steps to seasoned musicians pushing creative boundaries,” said Frank, Founder & CEO of Aeroband. “We’re excited to showcase our innovations at SXSW, where creativity and technology come together.”

Smart Music Innovation at SXSW

Aeroband Guitar: Aeroband Guitar is an all-in-one, portable instrument that combines cutting-edge technology with an immersive musical experience. The silent practice feature lets you practice the guitar without disturbing others, while the multi-tone functionality, including piano tones, expands your sound options for a richer experience. For creators, the MIDI controller functionality allows seamless integration with digital music workstations, enabling endless music production and composition possibilities. Whether learning or creating, the Aeroband Guitar is a versatile tool that helps you express your musical creativity.

  • Multi-tone
  • MIDI Controller
  • Silent Practice

PocketDrum: PocketDrum is a revolutionary air drumming instrument that turns any surface into a responsive drum kit. Its quiet design ensures that musicians can practice without disturbing others, and its MIDI functionality connects to digital music platforms, allowing for endless creative possibilities. Whether at home or on the go, PocketDrum provides an immersive drumming experience that fits into any lifestyle.

  • Play Anytime, Anywhere
  • No Disturb
  • MIDI Controller

Both the Aeroband Guitar and PocketDrum are available for purchase directly from the Aeroband website or on Amazon, offering easy access to these innovative instruments for music enthusiasts everywhere. During SXSW, enjoy exclusive event discounts that unlock even greater value for your musical journey. Whether you’re just starting or already an experienced musician, these products are designed to unlock your full musical potential.

  • Aeroband Guitar: Available for $459.00
  • PocketDrum: Available for $179.00

For more information, please visit https://www.aeroband.net/pages/sxsw

About SXSW

South by Southwest (SXSW) is an annual festival in Austin, Texas, celebrating the convergence of technology, music, film, and culture. It has become a global platform for innovative creators, artists, and thinkers to share ideas and experiences. The 2025 SXSW Festival will take place from March 7th to March 15th.

About Aeroband

Aeroband is the world’s best smart musical instrument company, revolutionizing music technology with products like the Aeroband Guitar and PocketDrum. Designed for music lovers of all levels, Aeroband enables users to explore their musical creativity anytime, anywhere. Whether a beginner or a professional, Aeroband provides intuitive, innovative tools that empower you to express yourself through music.

Contact:
Lola Xu
Public Relations
Aeroband
Email: lola@aeroband.net
Website: https://www.aeroband.net/